A growing number of FDA-approved innovators and biosimilars are being manufactured at China-based facilities as biopharma takes interest in the…
Read More
US Life Sciences Investment Woes Leave Nation Vulnerable as China Cultivates Future Big Pharma Competitors
San Diego, CA – The landscape of global biopharmaceutical innovation is undergoing a significant shift, with concerns mounting among investors…
Read More
Akeso Secures NMPA Approval for Gumokimab to Treat Plaque Psoriasis in China
Akeso has announced a significant milestone in its therapeutic pipeline with the National Medical Products Administration (NMPA) of China granting…
Read More
China Ascends to Global Clinical Trial Leadership as Immunology and Metabolic Diseases Emerge as Key Growth Areas
As the global pharmaceutical industry navigates the dynamic landscape of clinical research, China has firmly established its dominance in trial…
Read More
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China, Bolstering HBV Treatment Landscape
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
RoosterBio and MineBio Forge Exclusive Partnership to Accelerate MSC and Exosome Therapies in China
RoosterBio, a prominent innovator in the field of mesenchymal stem cell (MSC) and exosome bioprocessing, has announced an exclusive distributor…
Read More
